Pfizer Inc. (PFE) Cash Flow Statement

The gap between net income and operating cash flow is stark: in Q2 2026, a $246 million net loss contrasted with $835 million in operating cash flow, implying significant non-cash charges like D&A and possibly inventory write-downs. Conversely, Q4 2024 saw OCF/NI of 16.68, driven by a $2.9 billion working capital inflow, which may not be sustainable. This volatility suggests that reported earnings are not a reliable indicator of cash generation, and investors should focus on cash-based metrics.

The FCF trajectory shows a recovery from the trough in mid-2024, but the current level is far below the robust cash generation of Q3-Q4 2024, when FCF margins exceeded 30%. This suggests that the COVID-related revenue windfall has faded, and the company is now operating in a more normalized, lower-margin environment. The Q2 2026 FCF of $302 million is barely positive, indicating that capital expenditures and working capital demands are consuming a significant portion of operating cash flow.

Pfizer's capex-to-revenue ratio has remained relatively stable, but the absolute level of spending is substantial, reflecting investments in sterile injectables and biologics capacity. The company appears to be prioritizing growth capex to support its oncology and vaccine platforms, which may pressure near-term FCF. However, the moderate capital intensity relative to peers like LLY (which has higher capex) suggests Pfizer is not over-investing, but the need to replace aging assets and support new launches could keep capex elevated.

The working capital line is a major source of quarterly cash flow volatility, with large swings in receivables, inventory, and payables. The negative working capital change in Q2 2026 suggests a build-up in inventory or a slowdown in collections, which may indicate softer demand or supply chain challenges. Conversely, Q4 2024's positive $2.9 billion change was likely driven by collections of COVID-related receivables. This volatility makes it difficult to assess the underlying efficiency of working capital management, but it appears that Pfizer is not consistently optimizing its cash conversion cycle.

Pfizer's dividend payments are substantial and have remained constant at around $2.4 billion per quarter, which is a significant drain on cash flow. In Q2 2026, dividends exceeded operating cash flow, indicating that the company is borrowing or using existing cash reserves to fund the dividend. With no share repurchases and ongoing acquisition activity, the capital deployment strategy appears heavily skewed toward returning cash to shareholders, which may be unsustainable if operating cash flow does not improve. The sustainability of the dividend is a key risk, especially given the patent cliff and IRA pricing pressures.

While cumulative operating cash flow has exceeded net income over the period, the trend is not consistent. In 2024, operating cash flow was strong, but in 2025 and 2026, it has been more volatile. The cumulative gap between net income and operating cash flow is positive, indicating that earnings are backed by cash, but the recent quarters show a divergence where net income is lower than operating cash flow, which may be due to non-cash charges. This suggests that the quality of earnings is improving, but investors should monitor whether this trend continues as the company faces revenue declines.